Search for

Search Results

17 Search Results

McGill, Yale and Universities of Pennsylvania and Massachusetts Join PanFAM-1, the Largest Ever Prospective Multicenter Clinical Study for Early Detection of Pancreatic Cancer

New centers give study near complete coverage of North American FPC sites in drive to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer — Immunovia AB today announced that four additional North American Familial Pancreatic Cancer (FPC) sites are to participate in PanFAM-1, the largest ever prospective study looking […]

Pancreatic cancer’s addiction could be its end

Cancer cells are often described as cells “gone bad” or “renegade.” New research reveals that in some of the deadliest cases of pancreatic cancer, these rebellious cells have an unexpected addiction. Now, scientists are investigating if that addiction can be used to bring about a tumor’s end. Cold Spring Harbor Laboratory (CSHL) research recently published […]

Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields

-Novocure (NASDAQ: NVCR) announced today that the results of its PANOVA phase 2 pilot trial have been published in Pancreatology. The PANOVA pilot trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields in patients with advanced pancreatic cancer whose tumors could not be removed surgically and who had not received chemotherapy or radiation therapy prior to entering the clinical trial.

Ipsen Presents Real-World Pancreatic Cancer Data on ONIVYDE® at the European Society for Medical Oncology (ESMO) 2018 Annual Congress

Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced results from a retrospective, observational analysis examining the real-world dosing patterns of patients with metastatic pancreatic cancer (mPC) treated with ONIVYDE® (irinotecan liposome injection), at this year’s European Society for Medical Oncology (ESMO) annual congress taking place in Munich, Germany, Oct. 19-23, 2018.

BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) (TASE: BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today disclosed additional data from the in-depth analyses of biopsies of the dual combination arm of the Phase 2a COMBAT/KEYNOTE-202 study, evaluating patients with metastatic pancreatic adenocarcinoma (PDAC) treated with BL-8040 in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside of the United States and Canada).

Switchable CAR T Cells May Be Safer in Pancreatic Cancer

Switchable chimeric antigen receptor (CAR) T cells with a switch directed towards human epidermal growth factor receptor 2 (HER2) in pancreatic ductal adenocarcinoma (PDAC) has similar efficacy as conventional HER2 CAR T cells while also having a greater control over treatment toxicities.

PDAC is the fourth leading cause of cancer-related deaths, with less than 20% of patients having resectable tumors. While CAR T-cell treatments have shown substantial efficacy in hematological malignancies, outcomes in solid tumors such as pancreatic cancer have been limited.

Killer cell immunotherapy offers potential cure for advanced pancreatic cancer

A new approach to treating pancreatic cancer using ‘educated killer cells’ has shown promise, according to early research by Queen Mary University of London.

The new cell-based immunotherapy, which has not yet been tested in humans with pancreatic cancer, led to mice being completely cancer-free, including cancer cells that had already spread to the liver and lungs.

Cancer stem cells use “normal” genes in abnormal ways

CDK1 is a “normal” protein – its presence drives cells through the cycle of replication. And MHC Class I molecules are “normal” as well – they present bits of proteins on the surfaces of cells for examination by the immune system. But a University of Colorado Cancer Center study published in the journal Cancer Research shows that a population of cancer cells marked by MHC Class I molecules and high CDK1 is anything but normal.

CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma

Cancers are comprised of heterogeneous subpopulations with various tumor-initiating capacities, yet key stem cell genes associated with enhanced tumor initiating capacities and their regulatory mechanisms remain elusive. Here we analyzed patient-derived xenografts from melanoma, colon, and pancreatic cancer tissues and identified enrichment of tumor-initiating cells in MHC class I-hi cells, where CDK1, a master regulator of the cell cycle, was upregulated.